Table 1 Compounds, abbreviations, Cmax concentrations, beating profile and CDI score for non teratogens and teratogens.

From: Transcriptome-based prediction of drugs, inhibiting cardiomyogenesis in human induced pluripotent stem cells

Compound

Abbreviation

Tested concentration [µM]

Beatinga

CDI score

1-fold Cmaxb

Non-teratogens

    

 Ampicillin

AMP

107

Yes

0.1c

 Ascorbic acid

ASC

200

Yes

0

 Buspirone

BSP

0.0244

Yes

0

 Chlorpheniramine

CPA

0.0304

Yes

0

 Dextromethorphan

DEX

0.15

Yes

0

 Diphenhydramine

DPH

0.3

Yes

0

 Doxylamine

DOA

0.38

Yes

0.03

 Famotidine

FAM

1.06

Yes

0

 Folic acid

FOA

0.38

Yes

0.03

 Levothyroxine

LEV

0.077

Yes

0.03

 Liothyronine

LIO

0.00307

Yes

0.06d

 Magnesium (chloride)

MAG

1200

Yes

0

 Methicillin

MET

140

Yes

0

 Ranitidine

RAN

0.8

Yes

0

 Retinol

RET

1

Yes

0

 Sucralose

SUC

2.5

Yes

0.2

Teratogens

    

 9-cis-Retinoic acid

9RA

1

No

1

 Acitretin

ACI

1.2

No

1

 Isotretinoin

ISO

1.7

No

1

 Atorvastatin

ATO

0.54

Yes

0

 Carbamazepine

CMZ

19

Yes

0.03

 Entinostat

ENT

0.2

Yes

0.2e

 Favipiravir

FPV

382

Yes

0

 Leflunomide

LFL

370

Yes

0.3f

 Lithium (chloride)

LTH

1000

Yes

0.2g

 Methotrexate

MTX

1

Yes

0.2

 Methylmercury

MEM

0.02

Yes

0.1h

 Paroxetine

PAX

1.2

Yes

0.2i

 Teriflunomide

TER

370

Yes

0.3j

 Thalidomide

THD

3.9

Yes

0.3

 Trichostatin A

TSA

0.01

Yes

0.1k

 Valproic acid

VPA

600

Yes

0.4

 Vismodegib

VIS

20

Yes

0

  1. aYes, if beating was observed; No, if beating was not observed.
  2. bΥes, if on day 14 was observed beating cardiomyocytes; No, if on day 14 were not observed any beating cardiomyocytes. The CDI score is defined as Cardiotoxicity Developmental Index. This index has a maximal value of 1, which is reached when all 31 genes from (Fig. 5E) are deregulated by a compound; likewise, it has a minimal value of 0 if no gene is deregulated. The CDI score is calculated only on the hiPSC-SBAD2 cells. The beating and cytoxocity refers to hiPSC-IMR90 as well as hiPSC-SBAD2 indicate a different deregulation pattern as the retinoinds and the 31 ‘’gold standard” genes.
  3. cTotal 3 out 31, 2 downregulated instead of up regulated like in retinoids.
  4. dTotal 7 out 31, 1 downregulated instead of up regulated like in retinoids.
  5. eTotal 6 out 31, 2 downregulated instead of up regulated like in retinoids, 3 upregulated instead of being downregulated like in retinoinds.
  6. fTotal 10 out 31, 4 downregulated instead of up regulated like in retinoids, 1 is upregulated instead of being downregulated like in retinoinds.
  7. gTotal 7 out 31, 5 downregulated instead of up regulated like in retinoids, 1 is upregulated instead of being downregulated like in retinoinds.
  8. hTotal 4 out 31, 3 downregulated instead of up regulated like in retinoids, 1 is upregulated instead of being downregulated like in retinoinds.
  9. iTotal 6 out 31, 1 downregulated instead of up regulated like in retinoids.
  10. jTotal 8 out 31, 3 downregulated instead of up regulated like in retinoids.
  11. kTotal 4 out 31, 1 downregulated instead of up regulated like in retinoids, 1 is upregulated instead of being downregulated like in retinoinds.